Curated News
By: NewsRamp Editorial Staff
August 01, 2024
Theriva Biologics Advances oncolytic virus therapies to improve survival rates for difficult-to-treat cancers
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Theriva Biologics is a leader in oncolytic virus therapies, targeting difficult-to-treat cancers, representing a significant competitive advantage in the oncology market.
- Theriva's oncolytic viruses, such as VCN-01, are designed to break down the tumor's protective barrier and improve tumor access by co-administered cancer therapies and the patient's immune system.
- Theriva's research and clinical trials aim to improve survival rates for difficult-to-treat cancers, making tomorrow better by offering hope and effective treatments for patients with different cancer types.
- Theriva's approach of using viruses to treat cancer is both novel and fascinating, offering a new perspective on cancer treatment and potential breakthroughs in the field of oncology.
Impact - Why it Matters
This news matters because it highlights the efforts of a company, Theriva Biologics, to address the challenges of treating difficult-to-treat cancers such as brain tumors and pancreatic cancers. The development of oncolytic virus therapies could potentially improve survival rates and provide new treatment options for patients with these types of cancer. It also demonstrates the ongoing progress and innovation in the field of cancer research and treatment.
Summary
Cancer Research UK reports that cancer survival rates have doubled in the last 40 years, but some types of cancer, such as brain tumors and pancreatic cancers, have seen little improvement. Theriva Biologics (AMEX: TOVX) is on a mission to change that. The company has developed oncolytic virus therapies to target difficult-to-treat cancers. Positive results have been announced from ongoing clinical trials, showing promise in treating a wide range of tumor types. Theriva is also collaborating with various institutions to develop next-generation oncolytic viruses and explore innovative approaches to prevent complications in cancer treatment.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Theriva Biologics Advances oncolytic virus therapies to improve survival rates for difficult-to-treat cancers
